ArticleTranslational andrology and urology2020
Compositional differences of gut microbiome in matched hormone-sensitive and castration-resistant prostate cancer.
Article in Translational andrology and urology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- The role of the human microbiome in prostate cancer: a systematic review from diagnosis to treatment.Prostate cancer and prostatic diseases · 2026Pooled it
- The Role of Gut Microbiome in Prostate Cancer: Current Evidence and Emerging Opportunities.Cancers · 2026Review
- Gut microbiota as a multifaceted modulator of prostate cancer: Mechanistic insights, therapeutic opportunities and clinical challenges (Review).Molecular medicine reports · 2026Review
- Unraveling the microbial landscape in prostate cancer: pathogenesis to therapy.NPJ biofilms and microbiomes · 2026Review
- Decoding Microbiome's Role in Prostate Cancer Progression and Treatment Response.Diseases (Basel, Switzerland) · 2025Review
- Ruminococcus and prostate cancer: new treatment opportunities on the gut-prostate axis.Medical oncology (Northwood, London, England) · 2025Review
- NK Cell-Microbiota Interaction Biomarker Strategy: Advancing Prostate Cancer Management.Biomolecules · 2025Review
- Reprogramming prostate cancer through the microbiome.Frontiers in medicine · 2025Review
- Advancing prostate cancer treatment: the role of fecal microbiota transplantation as an adjuvant therapy.Current research in microbial sciences · 2025Review
- Gut Microbiota, Human Blood Metabolites, and Esophageal Cancer: A Mendelian Randomization Study.Genes · 2024Article
- Microbiome Dysbiosis Is Associated with Castration Resistance and Cancer Stemness in Metastatic Prostate Cancer.International journal of molecular sciences · 2024Article
- Microbiome and Prostate Cancer: Emerging Diagnostic and Therapeutic Opportunities.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Gut microbiome: a novel preventive and therapeutic target for prostatic disease.Frontiers in cellular and infection microbiology · 2024Review
- A Holistic Approach to Hard-to-Treat Cancers: The Future of Immunotherapy for Glioblastoma, Triple Negative Breast Cancer, and Advanced Prostate Cancer.Biomedicines · 2023Review
- The human microbiome links to prostate cancer risk and treatment (Review).Oncology reports · 2023Review
- Body composition parameters were associated with response to abiraterone acetate and prognosis in patients with metastatic castration-resistant prostate cancer.Cancer medicine · 2023Article
- Role of microbiome and its metabolite, short chain fatty acid in prostate cancer.Investigative and clinical urology · 2023Review
- Potential role of gut microbiota in prostate cancer: immunity, metabolites, pathways of action?Frontiers in oncology · 2023Review
- Possibilities and limitations of using low biomass samples for urologic disease and microbiome research.Prostate international · 2022Review
- Prostate diseases and microbiome in the prostate, gut, and urine.Prostate international · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIt is known that gut microbiota can regulate cancer therapies. We hypothesized that gut microbiota may interact with androgen deprivation therapy (ADT) in the process of castration-resistant prostate cancer (CRPC). Here, the differences in gut microbiota between matched hormone-sensitive prostate cancer (HSPC) and CRPC were determined before and after ADT.
methodsWe profiled the fecal microbiota in matched HSPC and CRPC from 21 patients who received ADT at our urological center using 16S rRNA gene amplicon sequencing. Differences in microbiota were determined with α/β-diversity and LefSe analysis. Functional inference of microbiota was performed with PICRUSt.
resultsThe results showed that the gut microbial community in CRPC was significantly altered with increased abundance of several bacterial flora including genus
conclusionsMeasurable differences in the gut microbiota were identified between HSPC and CRPC. Functional validations are further needed to ascertain the underlying mechanism of these differential microbiota in the process of CRPC, and their potential as new targets to enhance ADT responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.